SEC Form 3 · accession 0000899243-18-011966
Evelo Biosciences, Inc. · EVLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Bodmer
Officer — See Remarks
Period of report
May 8, 2018
Accepted (ET)
May 8, 2018 · 8:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001694665
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 220,642 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $1.14 | holding | — | — | — | — | Oct 6, 2026 | Common Stock | 163,030 | — | D |
| Stock OptionF2 | $1.14 | holding | — | — | — | — | Oct 6, 2026 | Common Stock | 23,290 | — | D |
| Stock OptionF3 | $2.49 | holding | — | — | — | — | Sep 18, 2027 | Common Stock | 72,370 | — | D |
| Stock OptionF4 | $10.48 | holding | — | — | — | — | Apr 3, 2028 | Common Stock | 92,546 | — | D |
Explanation of responses
- F1The option vested as to 25% of the total grant on July 1, 2017 and has vested or will vest in equal quarterly installments over a three year period thereafter.
- F2The option vests and becomes exercisable as to 50% of the total grant on December 15, 2020 and as to the remaining 50% on December 30, 2021.
- F3The option vests and becomes exercisable as to 20% of the total grant on July 1, 2018, as to 5% of the total grant quarterly for the period from July 1, 2018 to July 1, 2019, and as to 7.5% of the total grant quarterly thereafter.
- F4The option vests and becomes exercisable as to 25% of the total grant on April 3, 2019 and vests in equal quarterly installments over a three year period thereafter.
Remarks
Chief Scientific Off. & Pres.of R&D Exhibit 24 - Power of Attorney.